ReviewFrontiers in pharmacology2025
Unveiling the power of
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Preclinical evaluation of puerarin for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of Qingre Lishi decoction for type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Fortification of Wheat Bread with Increasing Levels of Kudzu (Foods (Basel, Switzerland) · 2026Article
- Puerarin Alleviates Depression via Integrated Regulation of TLR4/MyD88/NF-κB Signaling and Gut Microbiota-Metabolic Axis.Neurochemical research · 2026Article
- Herbal Textual Research, Phytochemistry, Pharmacology and Toxicity of Atractylodis Rhizoma: A Comprehensive Review.Molecules (Basel, Switzerland) · 2026Review
- Solvent-Dependent Chemical Profiles and Biological Activities ofMolecules (Basel, Switzerland) · 2026Article
- Molecular Mechanisms and Therapeutic Potential of Puerariae Lobatae Radix in Bone Metabolism: A Comprehensive Review.Drug design, development and therapy · 2026Review
- Exploring the molecular mechanisms of Pueraria in Alzheimer's disease treatment using machine learning and network pharmacology.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aim of the study: To integrate information on the source of Materials and Methods: A comprehensive literature search (1975-2025) was conducted across ScienceDirect, Google Scholar, PubMed, Web of Science, CNKI, WFO (www.worldfloraonline.org), MPNS (https://mpsn.kew.org), Changchun University of Chinese Medicine Library collections, and SciFinder. Ancient applications were validated through analysis of classic Chinese medical literature. Results: PL is predominantly found in Asia, Europe, and America, with significant populations in China's Zhejiang, Jiangxi, Jiangsu, Guangdong, and Guangxi provinces. The plant comprises flavonoids, triterpenoids, and coumarins, including isoflavonoids like daidzein and puerarin, which are synthesized via diverse pathways. Metabolites produced from liver or intestinal reactions are crucial to PL's effectiveness. Key components include puerarin, daidzein, genistein, biochanin A, and formononetin. In China, PL is incredibly versatile, being used in a wide range of foods, teas, preservatives, dairy products, Conclusion: Its extensive biological activities benefit the human body, with particular emphasis on liver protection, anti-osteoporosis, and anti-diabetic effects. These attributes highlight the potential for developing health foods, revealing PL's promising prospects in the pharmaceuticals and nutritional healthcare industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.